Your mitochondria send signals, too.

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside mitochondrial 12S rRNA. It has been detected in human skeletal muscle and circulation and is being studied as a signal between mitochondrial metabolism and the rest of the cell.

In a study of 10 young men, a stationary-bike session increased endogenous MOTS-c measured in skeletal muscle and serum. That study measured the body’s own peptide response to exercise; it did not administer a MOTS-c drug product.

Cell and animal studies have measured AMPK signaling, glucose handling, skeletal-muscle metabolism, treadmill capacity, body composition, and other metabolic endpoints. Treatment results in people have not yet been published.

A 120-person randomized Phase 2a study is recruiting adults with prediabetes and overweight or obesity. The trial uses subcutaneous MOTS-c or placebo for 12 weeks and measures insulin sensitivity and metabolic markers. No results are posted yet.

The planned format is a 10 mg injection vial. Orders are closed. The availability update will include the exact substance, concentration, package, directions, storage, supply, price, states served, and refill timing.

If MOTS-c becomes available, the prescription will be filled by a licensed U.S. compounding pharmacy. The patient label will identify the finished formulation, concentration, storage instructions, and beyond-use date.

Published human treatment safety data are not yet available. A registered 120-person Phase 2a trial is recruiting, but no results have been posted. Rebody orders are closed.